- Migenix begins phase II study in chronic hepatitis C Messenger

[Guest guest]

Migenix begins phase II study in chronic hepatitis C Messenger

http://uk.biz./041015/241/f4ni7.html

he phase IIa study of antiviral agent MX-3253 will involve approximately 60

treatment-naive or interferon-intolerant hepatitis C virus (HCV) patients

(genotype I), divided into three dosing groups. The objective of the study is to

evaluate HCV viral loads at various time points during the study and at 12

weeks.

The study will also assess the safety of MX-3253 in HCV patients. Since MX-3253

has shown additive and/or synergistic effects with currently marketed products

in pre-clinical models, studies are also being planned to evaluate MX-3253 in

combination with currently marketed products.

MX-3253 (celgosivir) is an orally-administered, unique antiviral agent exerting

its effects through the inhibition of the mammalian cell enzyme,

alpha-glucosidase I. Alpha-glucosidase I inhibitors can inhibit the replication

of a broad range of enveloped viruses (including HCV) by preventing the correct

folding of their envelope glycoproteins.

MX-3253 has demonstrated efficacy in a surrogate model of HCV infection and has

been well tolerated in over 500 human subjects to date.

Migenix expects results of the study in the second quarter of 2005.

[Guest guest]

Migenix begins phase II study in chronic hepatitis C Messenger

http://uk.biz./041015/241/f4ni7.html

he phase IIa study of antiviral agent MX-3253 will involve approximately 60

treatment-naive or interferon-intolerant hepatitis C virus (HCV) patients

(genotype I), divided into three dosing groups. The objective of the study is to

evaluate HCV viral loads at various time points during the study and at 12

weeks.

The study will also assess the safety of MX-3253 in HCV patients. Since MX-3253

has shown additive and/or synergistic effects with currently marketed products

in pre-clinical models, studies are also being planned to evaluate MX-3253 in

combination with currently marketed products.

MX-3253 (celgosivir) is an orally-administered, unique antiviral agent exerting

its effects through the inhibition of the mammalian cell enzyme,

alpha-glucosidase I. Alpha-glucosidase I inhibitors can inhibit the replication

of a broad range of enveloped viruses (including HCV) by preventing the correct

folding of their envelope glycoproteins.

MX-3253 has demonstrated efficacy in a surrogate model of HCV infection and has

been well tolerated in over 500 human subjects to date.

Migenix expects results of the study in the second quarter of 2005.